Basic information Safety Supplier Related

5-(3-Aminoprop-1-yn-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride

Basic information Safety Supplier Related

5-(3-Aminoprop-1-yn-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride Basic information

Product Name:
5-(3-Aminoprop-1-yn-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride
Synonyms:
  • 5-(3-Aminoprop-1-yn-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride
  • Thalidomide-5-propargyne-NH2, HCl salt
  • Thalidomide-5-propargyne-NH2 HCl
  • 5-(3-Aminoprop-1-yn-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride?, Thalidomide-5-propargyne-NH2 HCl
  • Thalidomide-5-propargyne-NH2 (hydrochloride)
  • 1H-Isoindole-1,3(2H)-dione, 5-(3-amino-1-propyn-1-yl)-2-(2,6-dioxo-3-piperidinyl)-, hydrochloride (1:1)
CAS:
2490402-62-3
MF:
C16H14ClN3O4
MW:
347.76
Mol File:
2490402-62-3.mol
More
Less

5-(3-Aminoprop-1-yn-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride Usage And Synthesis

Uses

Thalidomide-5-propargyne-NH2 hydrochloride is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-propargyne-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTACs[1].

IC 50

Cereblon

References

[1] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-994. DOI:10.1016/j.stem.2020.07.019

5-(3-Aminoprop-1-yn-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochlorideSupplier

Daicel Chiral Technologies (China)CO.,LTD
Tel
021-50460086-9 15921403865
Email
han_yajun@dctc.daicel.com
Jilin Province Woda Biotechnology Co., Ltd.
Tel
13504435624
Email
1927928688@qq.com
Shandong Territorial sea Biological Technology Co., LTD
Tel
15092083467
Email
18660263263@163.com
ShenZhen Trendseen Biological Technology Co.,Ltd.
Tel
13417589054
Email
trendseenbio@gmail.com
Shanghai Easy CDMO Co.,Ltd
Tel
021-61734564 13854185395;
Email
info@easycdmo.com
More
Less